The p16 immunohistochemical (IHC) marker has been used increasingly as an adjunct to morphologic assessment of cervical biopsies in which the differential diagnoses include high-grade squamous intraepithelial lesion (HSIL) and its mimics. The objective of this study was to assess the potential influence of p16 IHC staining on the evaluation of cervical biopsy as observed through cytologic-histologic correlation (CHC). METHODS: Cervical biopsy samples that had cytologic diagnoses of either low-grade squamous intraepithelial lesion (LSIL) or HSIL and also had histologic follow-up were retrieved from the department database. CHC and the use of p16 IHC from 2 periods (group 1, 2008; group 2, 2014-2016) were compared and analyzed. RESULTS: Histology on 452 samples from patients who had prior LSIL cytology in group 1 yielded 126 benign (27.9%), 272 LSIL (60.2%), and 54 HSIL (11.9%) diagnoses. By comparison, 491 samples from the patients in group 2 yielded 106 benign (21.6%), 277 LSIL (56.4%), and 108 HSIL (22.0%) diagnoses. The difference in CHC discrepancies between the 2 groups was significant (P = .0001), mainly because of the increased diagnosis of HSIL in group 2. Although p16 IHC was not applied to any sample from group 1, it was performed on 141 of 491 samples (28.7%) from group 2. Further follow-up of patients who had histologic HSIL revealed that residual HSIL was identified significantly more often in those who did not have p16 IHC applied in the preceding cervical biopsy than in those did (P = .0004). A similar comparison was performed between 113 patients from group 1 and 152 patients from group 2 who had a prior diagnosis of HSIL cytology, and the difference was statistically insignificant. CONCLUSIONS:
INTRODUCTION
Cervical cytology has been a major tool in the screening of cervical cancers over the past 70 years and has greatly contributed to the reduction in mortality because of cervical cancer. 1 To ensure a high level of quality and to improve cytology diagnostic skills, the Clinical Laboratory Improvement Amendments of 1988 (CLIA) mandated that cytologic-histologic correlation (CHC) must be performed in cases with a cytologic diagnosis of high-grade squamous intraepithelial lesion (HSIL) or whenever cytologic and histologic diagnoses are discrepant. 2 Therefore, CHC has been considered 1 of the most important components of quality assurance and is routinely performed in CLIA-certified cytology laboratories.
phology alone to distinguish HSIL-especially grade 2 cervical intraepithelial neoplasia (CIN2)-from LSIL and squamous cell metaplasia can prove problematic, as demonstrated by significant interobserver and intraobserver discrepancies in both cervical cytology and biopsy diagnoses. [6] [7] [8] To address this issue, the Lower Anogenital Squamous Terminology Standardization Project (LAST), which was co-sponsored by the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology and published in 2012, recommends the use of p16 immunohistochemistry (IHC) as an adjudication tool when the differential diagnosis on hematoxylin and eosin-stained slides is morphologically between precancer (CIN2 or CIN3) and a mimic of precancer (eg, immature squamous metaplasia, atrophy, reparative epithelial changes, tangential section, etc). 9 In the years since this recommendation, the utility of p16 IHC in cervical biopsy has become far more prevalent in the above-mentioned scenarios.
The literature postulates that widespread application of p16 IHC might result in either upgrading or downgrading of squamous cell lesions in cervical biopsy specimens. 10, 11 In recent years, our laboratory's CHC has reflected an increase in discrepancies between cytologic LSIL and the follow-up histologic diagnosis, with an increase in HSIL being diagnosed on cervical biopsy. We hypothesize that the increase in use of p16 IHC in cervical biopsy specimens may have contributed to the increase in the discrepancies. In the current retrospective study, we compared CHC results from the periods before and after initiating the adjunct use of p16 IHC in cervical biopsy cases with a prior cytologic history of LSIL or HSIL.
MATERIALS AND METHODS
Specimens with a cytologic diagnosis of either LSIL or HSIL from patients who had histologic follow-up in 2 time periods (the year 2008 and the period 2014-2016) were retrieved from the department database. The specimens from 2008 were designated as group 1, representing the period when p16 IHC was not used in routine evaluation of cervical biopsies; and those from 2014 through 2016 (to match the number of the cases in group 1) were designated as group 2, representing the period when p16 IHC was used in daily practice in our laboratory. The cervical cytologic specimens were prepared with liquidbased technology and successfully scanned using the ThinPrep Imaging System (Hologic, Marlborough, MA) with manual full-slide review. Cytologic diagnostic criteria and terminology were based on The Bethesda System for Reporting Cervical Cytology. 12 Histologic follow-up included specimens from both cervical biopsy and endocervical curettage. The histologic diagnostic terminology and classification used consisted of the 3-tier CIN system and the 2-tier squamous intraepithelial lesion system with LSIL equaling to CIN1 and HSIL encompassing CIN2 and CIN3. 9, 13, 14 The "benign" category was defined as the absence of squamous cell intraepithelial lesions or malignancy in a biopsy sample. p16 IHC was performed on formalin-fixed, paraffin-embedded cervical biopsy specimens using CINtec p16 Histology kits (Ventana Medical Systems, Oro Valley, AZ) according to the manufacturer's instructions. The result of p16 IHC staining is determined based on the criteria stated in the LAST guideline. 9 Briefly, a p16-positive result was defined as strong and diffuse staining of the basal cell layer with extension upward involving at least 1 of 3 of the epithelial thicknesses. Our institution's standard procedures mandate that an initial CHC is carried out at the time of cervical biopsy sign-out by indicating whether the histologic diagnosis agrees with that of the preceding cervical cytology. For cervical squamous cell lesions, the discrepancies are classified as either minor or major. A case with a cytologic diagnosis of "negative for intraepithelial lesion or malignancy" but a histologic diagnosis of LSIL is a 1-step discrepancy (minor discrepancy), whereas a case with a cytologic diagnosis of negative for intraepithelial lesion or malignancy and a histologic diagnosis of HSIL is a 2-step discrepancy (major discrepancy). All cases with a discrepancy of 1 step or greater undergo full review. The intent of the review is mainly to identify error sources, such as interpretation and sampling error, on the part of either cytology or surgical pathology. In some cases, the results of the reviews will alter clinical management of the patients.
CHC data analyzed in this study encompass the cytologic diagnosis and the histologic diagnosis of the first follow-up biopsy, which typically took place within 12 months of prior cytologic examination. All diagnoses and p16 IHC interpretations were the originals and did not reflect the rare revision made in CHC. Information on further follow-up, mainly by loop electrosurgical excision procedure (LEEP) and the cone excision procedure in patients with HSIL, was retrieved whenever available.
In this retrospective study, we analyzed CHC results from the cases in which there was a prior cytologic diagnosis of LSIL or HSIL, comparing data gathered in the period before p16 IHC became commonly used versus data gathered after its implementation. Descriptive measures are reported as frequencies and percentages. CHC rate comparisons between groups were performed using chi-square tests. Statistical significance was based on P values < .05.
RESULTS
In total, 995 cases with a cytologic diagnosis of LSIL made in 2008 were retrieved, of which, 452 (45.4%) had a follow-up cervical biopsy and were included in group 1. The histologic diagnoses of the group 1 cervical biopsies consisted of 126 (27.9%) benign, 272 (60.2%) LSIL/CIN1, and 54 (11.9%) HSIL cases (of the HSIL cases, 38 were CIN2, and 16 were CIN 3). In total, 1177 cases with a cytologic diagnosis of LSIL made between 2014 and 2016 were identified, of which 491 (41.7%) had follow-up cervical biopsies and were designated as group 2. The histologic diagnoses for group 2 included 106 (21.6%) benign, 277 (56.4%) LSIL/CIN1, and 108 (22.0%) HSIL cases (of the HSIL cases, 76 were CIN2, and 32 were CIN3). The difference in CHC between the 2 groups was statistically significant (P = .0001), mainly because of the substantial increase in the HSIL diagnoses (and, in particular, CIN2 diagnoses) in group 2. p16 IHC was not applied to any cases from group 1, whereas it was applied to 141 of 491 cases (28.7%) from group 2. Of the cases stained with p16, 58 were interpreted as negative, and 83 were interpreted as positive. The final biopsy diagnoses of the 58 p16-negative cases comprised 7 benign and 51 LSIL/CIN1 cases. All 83 p16-positive cases were diagnosed as HSIL, including 72 CIN2 and 11 CIN3 cases (Table 1) . We further subdivided group 2 into 2 groups based on whether p16 IHC was used. A significant difference in CHC was noted only between group 1 and the portion of group 2 cases that used p16 IHC (P = .00001). An equivalent analysis performed on group 1 and the non-p16 subset of group 2 cases (the p16-naive group) did not produce a statistically significant result (P = .076).
Combining groups 1 and 2, in total, 162 cases that had a prior cytologic LSIL result were diagnosed as HSIL on the initial cervical biopsy. Among them, 100 had further histologic follow-up with either LEEP/cone excision (84 cases) or additional cervical biopsy/endocervical curettage (16 cases). Diagnostic information was divided into 2 groups based on whether p16 IHC was applied in the preceding biopsy. The p16-naive group exhibited more frequent residual HSIL, whereas the group that underwent p16 IHC exhibited more frequent LSIL. The difference was statistically significant (P = .0004) ( Table 2.) Similar comparisons were made between cases that had a cytologic diagnosis of HSIL. From a total of 143 cases of cytologic HSIL diagnosed in 2008, 113 (79.0%) had a follow-up cervical biopsy (group 1). By comparison, 152 of 181 cases (84.0%) had a follow-up cervical biopsy diagnosed from 2014 to 2016 (group 2). The histologic diagnoses of group 1 versus group 2 were as follows: benign, 9 (8.0%) versus 8 (5.3%), respectively; LSIL/CIN1, of 152 cases (38.8%) in group 2 had applied p16 IHC in addition to morphologic assessment. In group 2, the histologic diagnoses of the 13 p16-negative cases consisted of 4 benign and 9 LSIL/CIN1. All 46 p16-positive cases were diagnosed as HSIL, including 34 CIN2, 10 CIN2/CIN3, and 2 CIN3 cases. The difference in CHC between the 2 groups was statistically insignificant (Table 3) .
DISCUSSION
According to CLIA requirements, CHC is routinely performed in cytology laboratories in the United States. Because there is no widely accepted standard protocol available, CHC is primarily administered according to protocols developed in individual laboratories. 15 In general, CHC is performed concurrently with follow-up cervical biopsy sign-out (real-time) and/or at periodic, retrospective correlations performed at established intervals. Some studies argue that the gap between initial cytology and follow-up histology should be limited to less than 6 months for optimal results, because longer gaps could result in noncorrelation caused by regressing or newly developed lesions. Other studies propose that intervals of up to 12 months may be acceptable. [15] [16] [17] In our institution, the overwhelming majority of cervical biopsies are obtained within 12 months of the precipitating cervical cytology evaluation, and both real-time and periodic CHC are used.
In the current study, our CHC data comprised diagnoses of cervical cytology and their first follow-up biopsies. The data incorporated all of the original diagnoses and p16 IHC interpretations without amendments. This study explores the potential influence of p16 IHC on the diagnosis of squamous cell lesions in cervical biopsy specimens and on CHC. It is worth noting that none of the authors rendered the original biopsy diagnoses, and the exact circumstances surrounding the individual decisions to include or omit p16 IHC were not known to the authors, although, in general, they were based on the LAST guidelines. 9 In recent years, review of our institution's CHC revealed an increase in cytologic-histologic discrepancies. Among cases with a cytologic diagnosis of LSIL, 11.9% were identified as HSIL on follow-up cervical biopsy in 2008, and that percentage increased to 22% during 2014 through 2016. This finding, coupled with the observation that there were no significant changes in our laboratory personnel over the same period, provided the impetus for the current study. The increased discrepancy may have resulted from increased under-calling of HSIL in cytology, improved detection of, or over-calling HSIL on cervical biopsies in the recent period. The arguments Cancer Cytopathology December 2018
against cytology under-calls in the study periods included: 1) no significant changes in the staff or cytopreparation in our laboratory, 2) the cytology cases with discordant histology were reviewed by the same senior cytotechnologists and a cytopathologist in CHC and did not reflect a significant difference in cytology under-calls for either period, and 3) the percentages of the cases with a cytologic diagnosis of HSIL have been falling consistently into the median (50th) percentiles annually reported by the College of American Pathologists. Conversely, the most significant change in cervical biopsies was the increased use of p16 IHC after publication of the LAST recommendations. In reviewing the discrepant cases in CHC, a portion of CIN2 diagnosed on cervical biopsy with positive p16 IHC were cases that were morphologically equivocal and might have been called CIN1 (Fig. 1) or, potentially, squamous metaplasia (Fig. 2) without the IHC, although it is problematic to enumerate such cases because of inherent interobserver variability. We hypothesized that the increased application of p16 IHC may mediate the increase in HSIL diagnoses by increasing the detection of HSIL, upgrading otherwise under-called histology, or potentially overcalling HSIL on cervical biopsies. Our results demonstrate that significant discrepancies in CHC occurred only when p16 IHC was used, signifying that the stain potentially may affect CHC by upgrading squamous lesions from benign or LSIL to HSIL, and to CIN2 in particular. We also gave consideration to the premise that negative p16 IHC results may have a downgrading influence, but this was not statistically supported by the finding that CHC was not affected by the utility of p16 IHC in cases with prior HSIL cytology. An analysis of further follow-up of LEEP/ cone excisions in patients with histologic HSIL revealed that residual HSIL was more common for cases in which p16 IHC was not applied to the prior biopsy, whereas LSIL was identified more frequently for cases in which HSIL in the prior biopsy was diagnosed in conjunction with a positive p16 IHC stain. These results indicate that p16 IHC might have resulted in some cases being overcalled or, at the least, that the prognoses of HSIL diagnosed with and without p16 IHC may be different. Numerous studies in the literature explore the role of the p16 IHC staining for the classification of cervical squamous lesions and predicting their progression. [18] [19] [20] [21] [22] [23] [24] The p16 tumor-suppressor protein is well studied and involves regulation of the cell growth cycle. In the context of cervical squamous cell lesions, p16 serves as a surrogate biomarker indicating the incorporation and activation of HPV oncogenes E6 and E7 within the genome of the host cells. Theoretically, therefore, overexpression of p16 in cervical lesions suggests the presence of unregulated cell growth, ie, a neoplastic process. Most of the literature demonstrates that p16 IHC may improve interobserver variability in the histologic diagnosis and grading of cervical squamous lesions. 19, 21, 25 In a study evaluating 1455 cervical biopsies, discovered that p16 IHC was 86.7% sensitive and 82.8.% specific for a CIN2-positive diagnosis. 21 A systemic review of the literature and meta-analysis established that the level of agreement among pathologists for a CIN2-positive diagnosis was significantly higher when p16 IHC was used in combination with histology (κ, 0.73; 95% confidence interval, 0.67-0.79) compared with histology alone (κ, 0.41; 95% confidence interval, 0.17-0.65). 25 On the basis of the literature and expert opinion, the LAST guidelines recommend judicially implementing p16 IHC as an adjudication tool when the differential diagnosis on hematoxylin and eosin-stained slides is morphologically between precancer (CIN2 or CIN3) and a mimic of precancer. 9 Since its implementation, p16 IHC has been applied increasingly in the above-mentioned scenarios. Unfortunately, there are some unsolved issues associated with the use of p16 IHC in the diagnosis of cervical squamous cell lesions. First, the LAST guidelines define positive p16 IHC staining as a strong and diffuse block of nuclear or nuclear plus cytoplasmic staining of the basal cell layer with upward extension involving at least 1 of 3 of the epithelial thicknesses. Positive p16 IHC supports a categorization of precancer (ie, CIN2 and CIN3), whereas negative or nonblock-positive staining strongly favors an interpretation of LSIL or non-HPVassociated pathology. 9 However, in daily practice, p16
IHC staining patterns are frequently ambiguous, which complicates their evaluation. Figure 1B provides an example of a p16 IHC stain that was interpreted as positive; however, it may be interpreted differently by others. In a study by Liu et al, such equivocal cases accounted for up to 23% of p16 IHC stains. 26 Second, based on the literature, p16 IHC was positive in at least 30% of adjudicated CIN1 cases and negative in some HSIL cases, a finding that confounds the widespread utility of p16 IHC. 9, 18, 27, 28 Differentiating CIN2 from p16-positive CIN1 is a dubious process, in terms of both morphology and clinical significance. Although 1 study contends that p16 IHC may result in CIN2 being downgraded, 10 others (including the current study) argue that it can lead to increased upgrading of LSIL to HSIL. 11 Our study demonstrated more frequent LSIL diagnoses on follow-up LEEP/cone excisions for cases in which an HSIL diagnosis on the previous biopsy was aided by a positive p16 IHC result, suggesting potential overcall of some of those cases. Third, the LAST guidelines estimate that the magnitude of p16 IHC application when used according to recommendations should be <25% of all cervical biopsy specimens. 9 Our study indicates that the overall use of p16 IHC exceeded 30% at our institution. The LAST guidelines recommend against the use of p16 IHC as a routine adjunct to the histologic assessment of biopsy specimens with morphologic interpretations of negative, CIN1, and CIN3, except for some special circumstances, such as a prior cytologic interpretation of HSIL; atypical squamous cells (ASC), cannot rule out HSIL (ASC-H); ASC of undetermined significance (ASC-US)/HPV16-positive; or atypical granular cells, not otherwise specified. 9 Estimates in the literature indicate that >70% of LSIL/CIN1 cases are positive for high-risk HPV (hr-HPV), 29-31 a significant portion of which also may have at least ASC-US/HPV16-positive as a preceding diagnosis. Such a history would make a case with morphologic LSIL/CIN1 eligible for p16 IHC. Our institution performs p16 IHC on equivocal CIN2 cases as well as on cases that are morphologically CIN1 or less but possess the aforementioned high-risk factors. In the case presented in Figure 1 , an ASC-US/hr-HPV-positive history contributed to the decision to perform p16 IHC. There were no clear guidelines on how to interpret positive p16 results under those circumstances. Finally, a major goal of CHC is uncovering error sources, with the intent of facilitating quality improvement. Errors may result from interpretation or sampling variability or stem from other causes. Some equivocal CIN2 cases that required p16 IHC to confirm the diagnosis exhibited no evidence of HSIL on the corresponding cytology samples. Cytology sampling error did not explain the discrepancy in such cases, because the morphology of the cells of interest even in cervical biopsies did not meet cytologic criteria for HSIL. For example, in Figure 1 , the discrepancy in HSIL samples between cytologic and histologic diagnoses may result from neither interpretation nor sampling error on the part of cytology, and repeat cytology may not rectify such a discrepancy. In such cases, "under-calling" may become an inherent disadvantage of cervical cytology. Awareness of this potential development is essential to optimal patient care, because it is not uncommon for clinicians to rely on cytologic interpretation in guiding their patient care.
In summary, the current results establish that the use of p16 IHC may have a significant influence on the diagnosis of squamous cell lesions in cervical biopsy specimens by increasing the rates of detection of HSIL, upgrading otherwise under-called histology, or potentially overcalling HSIL on cervical biopsies, thereby affecting the clinical management of patients as well as CHC.
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